Last reviewed · How we verify
Aclidinium Bromide 400 µg
Aclidinium bromide is a muscarinic M3 receptor antagonist that blocks acetylcholine signaling in airway smooth muscle, causing bronchodilation.
Aclidinium bromide is a muscarinic M3 receptor antagonist that blocks acetylcholine signaling in airway smooth muscle, causing bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Aclidinium Bromide 400 µg |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Aclidinium is a long-acting anticholinergic (LAMA) that selectively antagonizes M3 muscarinic receptors on airway smooth muscle and mucus glands. By blocking acetylcholine-mediated bronchoconstriction, it produces sustained airway relaxation and improved airflow. The drug is rapidly hydrolyzed by non-specific esterases, minimizing systemic anticholinergic effects.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Urinary retention
Key clinical trials
- Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (PHASE3)
- Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (PHASE3)
- Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aclidinium Bromide 400 µg CI brief — competitive landscape report
- Aclidinium Bromide 400 µg updates RSS · CI watch RSS
- AstraZeneca portfolio CI